MedTrace Logo

Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

NCT06857747 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-03-04

No results posted yet for this study

Summary

This study aims to explore the efficacy of Disitamab vedotin in combination with metronomic chemotherapy in advanced breast cancer. By integrating the rapid onset of action of Disitamab vedotin with the characteristics of metronomic chemotherapy, the study seeks to further improve patients' response rates and enhance their quality of life, building upon the extension of patient survival.

Conditions

Interventions

DRUG

Capecitabine

metronomic capecitabine, 500 mg, tid， po

DRUG

Vinorelbine

metronomic vinorelbine, 40mg/d, TIW1, po

DRUG

Etoposide

metronomic etoposide, 50mg/d, po

Sponsors & Collaborators

  • QIAO LI

    lead OTHER

Principal Investigators

  • Qiao Li, Dr. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-12-01
Completion
2026-04-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06857747 on ClinicalTrials.gov